Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merlin L Robb

Showing results (351-360 of 358) with videos related to

Pageof 36
Sort By:
You have reached the last page of results.This site can display upto 358 results.
Cell Reports|August 10, 2023
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopesRajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, et al.
Plos Pathogens|August 4, 2015
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesSampa Santra, Georgia D Tomaras, Ranjit Warrier, et al.
Plos One|November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Lancet (London, England)|July 27, 2018
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H Barouch, Frank L Tomaka, Frank Wegmann, et al.
Journal of Virology|May 16, 2014
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trialAndrew J Gartland, Sue Li, John McNevin, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
Nature Medicine|February 5, 2020
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Rajeshwer S Sankhala, Gregory D Gromowski, et al.
Immunity|March 17, 2019
Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected IndividualShelly J Krebs, Young D Kwon, Chaim A Schramm, et al.
Pageof 36

Showing results (351-360 of 358) with videos related to

Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 358 results.
Cell Reports|August 10, 2023
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopesRajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, et al.
Plos Pathogens|August 4, 2015
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesSampa Santra, Georgia D Tomaras, Ranjit Warrier, et al.
Plos One|November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Lancet (London, England)|July 27, 2018
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H Barouch, Frank L Tomaka, Frank Wegmann, et al.
Journal of Virology|May 16, 2014
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trialAndrew J Gartland, Sue Li, John McNevin, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
Nature Medicine|February 5, 2020
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Rajeshwer S Sankhala, Gregory D Gromowski, et al.
Immunity|March 17, 2019
Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected IndividualShelly J Krebs, Young D Kwon, Chaim A Schramm, et al.
Pageof 36